On hospital day 2, an EGD showed extensive esophagitis as well as a 3-cm wide opening in the distal esophagus at 32 cm from the incisors, exposing multiple bronchi (Figures 5 and 6). Figure 5: EGD at ...

Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) approving a novel oral pill that helps prevent motion-induced vomiting – the first ...

Nereus is the first new pharmacologic treatment for motion sickness approved in over four decades, highlighting a significant advancement in the field. Motion sickness affects military operations and ...

It is well known informally that many radiation oncologists dispute RINV as being legitimate concerns for their patients. There are many explanations for this view. Treatments with prominent ...

Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial From March 2022 to December 2023, a ...

Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter? Supported in part by the Harold and Shirley Lederman Chair in Psychosocial Oncology and Palliative Care, ...

(HealthDay News) — Varubi (rolapitant) has been approved by the U.S. Food and Drug Administration to prevent delayed phase chemotherapy-induced nausea and vomiting. Varubi, a substance P/neurokinin-1 ...

The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side effects than older drugs.

Bulimia nervosa is an eating disorder characterized by cycles of binge eating and purging through methods like self-induced vomiting or taking laxatives. In the US, it will affect 1.5% of women and up ...

It seems like there’s a threshold when people can become vulnerable to the cannabis induced vomiting condition, and that threshold is different for everyone. Chronic cannabis use is increasingly ...